Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
CO43810
Hoffmann-La Roche
CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)
1 trial -
CO45813
Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer
1 trial -
CO46274
Hoffmann-La Roche
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation
1 trial -
CORT125134-557
CORCEPT THERAPEUTICS INC
Gynecological Cancers
1 trial -
CPGJ602
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Metastatic Colorectal Cancer
2 trials -
CPKC412A2218
Novartis Pharmaceuticals
untreated FLT3-mutated Acute Myeloid Leukemia
1 trial -
CPT002/2018/PO001
Fondazione Telethon ETS
Metastatic colorectal cancer
1 trial -
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Jazz Pharmaceuticals Ireland Limited
Colorectal Neoplasms
1 trial -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Lymphoid Leukemia
1 trial -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Leukemia, Myeloid, Acute
1 trial -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia (AML)
2 trials -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
7 trials -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia (AML) in Remission
1 trial -
CPX-351
Jazz Pharmaceuticals Ireland Limited
Myeloid Neoplasm
1 trial -
CR-001
CRESCENT BIOPHARMA, INC.
Locally Advanced / Metastatic Solid Tumors
1 trial -
CR6086-1-04
Alphapharm Pty Ltd
Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers
1 trial -
CRB-601 monoclonal antibody
Corbus Pharmaceuticals Holdings
Solid Tumor
1 trial -
CRB-701
Corbus Pharmaceuticals Holdings
Solid Tumor, Adult
1 trial -
CRISP ITCC-053
Disc Medicine
Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)
1 trial -
CRN09682
Crinetics Pharmaceuticals Europe GmbH
SST2-positive Neuroendocrine Neoplasms
1 trial -
CRN09682-191
Lacuna Pharma Pty Ltd
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults
1 trial -
CS1001
Cstone Pharmaceuticals Ireland Limited
Advanced Refractory Solid Tumors
1 trial -
CSET 2020/3187
The George Institute
Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC
1 trial -
CSET 2022-3571
The George Institute
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.
1 trial -
CSET 2025/4053
The George Institute
Breast cancer
1 trial -
CSET N° 2017/2523
The George Institute
Pancreatic well differentiated neuroendocrine tumors (NET)
1 trial -
CSET N° 2020/3188
The George Institute
Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.
1 trial -
CSET N°2016/2454
The George Institute
Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT
1 trial -
CSET N°2017/2536
The George Institute
Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)
1 trial -
CSET N°2020/3138
The George Institute
Advanced hepatocellular carcinoma
1 trial -
CSET n° 2020/3210
The George Institute
Untreated small triple negative breast cancer
1 trial -
CSIIT-Q115
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Small Cell Lung Cancer
1 trial -
CT-011
Teva Pharma GmbH
Primary Hepatocellular Carcinoma
1 trial -
CT053PTSA
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Renal Cell Cancer Metastatic
1 trial -
CT053PTSA
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non-small Cell Lung Cancer
1 trial -
CT7001, PF-07850327 round
Pfizer Australia Pty Ltd
Advanced or Metastatic Breast Cancer
1 trial -
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer
1 trial -
CTX-009 (ABL001)
Compass Therapeutics
P1b: Advanced Solid Tumors
1 trial -
CTX112
S.A.
B-cell Lymphoma
1 trial -
CTX131
S.A.
Clear Cell Renal Cell Carcinoma
1 trial -
CTX131
S.A.
T Cell Lymphoma
1 trial -
CUE-101
Cue Biopharma
Head and Neck Squamous Cell Carcinoma
1 trial -
CUE-101
Cue Biopharma
Oropharyngeal Squamous Cell Carcinoma
1 trial -
CX-072
CytomX Therapeutics
Solid Tumor
2 trials -
CX-2009
CytomX Therapeutics
Neoplasms
1 trial -
CX-2009
CytomX Therapeutics
Solid Tumor, Adult
1 trial -
CX-2029
CytomX Therapeutics
Solid Tumor, Adult
1 trial -
CYCAD-1(D8470C00001)
AstraZeneca AB
Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.